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In 1960, the first recurrent chromosomal rearrangement in human malignancies was iden-tified by Nowell and Hungerford in chronic myelogenous leukemia and described as the 
Philadelphia chromosome, which is currently recognized as the BCR-ABL translocation. 
The activated ABL tyrosine kinase, the fusion protein product from this rearrangement, 
also became the first defined molecular target against which a tyrosine kinase inhibitor was 
successfully developed.1 Since the introduction of chromosomal banding techniques in the 
1970s, which enabled easier detection of these chromosomal rearrangements, numerous 
recurrent rearrangements have been reported across many types of hematopoietic malig-
nancies and in solid tumors. In fact, recurrent RET rearrangements in papillary thyroid car-
cinomas were the first discovered chromosomal translocations involving a tyrosine kinase 
in solid tumors.2,3
In lung cancer, there has been a recent profusion of new activating gene fusion dis-
coveries, beginning with the discoveries of EML4-ALK fusion genes and ROS1 fusions.4,5 
Recently, with the advent of systematic genome-wide sequencing technologies, chromo-
somal rearrangements of other tyrosine kinases such as RET,6–9 NTRK1,10 FGFR3,11–13 and 
NRG1 ligand fusions14 have been identified. With many ongoing preclinical and clinical 
studies to test the efficacy of kinase inhibitors for such aberrantly activated molecules, a 
rapid introduction of accurate and sensitive diagnosis of those chromosomal rearrange-
ments has become increasingly important to identify patients who may benefit from these 
therapeutics. Current techniques to detect these chromosomal rearrangements include 
a break-apart fluorescence in situ hybridization (FISH) assay, a fusion FISH assay on 
unstained tissue slides, and reverse-transcriptase polymerase chain reaction (RT-PCR) on 
RNA samples from fresh frozen tissue specimens. In addition, targeted sequencing using 
hybrid capture followed by next-generation sequencing on DNA samples has been used as 
a detection method (See Table 1 for details).
The diagnosis of RET fusions is of increasing potential clinical importance because 
response to cabozantinib has already been reported in some patients,15 and numerous small 
molecule RET inhibitors are currently under investigation. Analyzing fusion breakpoints 
not only can lead to a better understanding of the molecular mechanisms that generate 
these rearrangements but also can help in the design of better detection methods. The study 
by Mizukami et al.16 in this issue describes the structures of breakpoint junctions involv-
ing the RET oncogene of 16 lung adenocarcinoma samples. Breakpoints from 14 samples 
with documented KIF5B-RET fusion transcripts by RT-PCR were identified using targeted 
genomic PCR followed by Sanger sequencing. Breakpoints from two samples with docu-
mented CCDC6-RET fusions by break-apart and fusion FISH assays were identified using 
targeted next-generation sequencing, with capture probes targeting the exons and introns 
spanning across exons 7 to 12 of the RET gene. This study also analyzed two previously 
published DNA sequences from lung adenocarcinomas with rearrangements involving the 
RET gene. The authors’ findings are in concordance with previous studies that observed 
genomic breakpoints in a few confined genomic regions spanning kilobases, but not at 
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specific genomic loci, and without significant enrichment of 
nucleotide motifs or chromatin features that would make them 
susceptible to breaks.17–20
Efforts to analyze these breakpoints at the sequence 
level have identified relatively consistent reciprocal rearrange-
ments with small insertion or deletion of a few base pairs in 
chemotherapy-related leukemia or radiation-induced papil-
lary thyroid carcinomas, whereas broader range stretches of 
DNA insertion, deletion, or duplication have been observed in 
spontaneous cancers.21,22 Mizukami et al. further analyzed the 
breakpoint sequences to infer which DNA repair mechanisms 
were involved to illegitimately rejoin the DNA ends of fusion 
partners and found that while many of the events are reciprocal 
inversions, there are cases of nonreciprocal rearrangements. 
Unfortunately, the authors were unable to analyze sequences 
on the other end of nonreciprocal breakpoint junctions, as 
captured-based sequencing data for these cases were not avail-
able. Nevertheless, these findings have significant implication 
to the interpretation of results from  break-apart FISH assays in 
a clinical setting. Similar to the cases of  EML4-ALK fusions,23 
their results suggest it is of positive diagnostic value to only 
detect a probe corresponding to the 3′ end of the RET gene.
This study identified diverse DNA repair mechanisms 
for breaks. In most cases, a lack of sequence homology at 
breakpoint junctions implicated nonhomologous end join-
ing as the repair mechanism. In four cases with reciprocal 
rearrangements, duplication of sequences at both ends of 
the breakpoint junctions implicated break-induced replica-
tion repair. This is in contrast to repair mechanisms observed 
in papillary thyroid carcinomas, where nonhomologous end 
joining has only been observed.21,22 Although the exact fac-
tors that cause DNA breaks or choice of DNA repair pathways 
are unknown, the difference in repair mechanisms between 
lung adenocarcinoma and papillary thyroid carcinomas may 
be explained by a difference in carcinogenic insults in these 
two cohorts. Evidence of break-induced replication repair in 
lung adenocarcinoma suggests single-stranded breaks occur 
in addition to double-stranded breaks; however, there was no 
difference in features of breaks or DNA repair mechanisms 
between never-smokers and ever-smokers; therefore, the role 
of smoking-related carcinogens in the genesis of RET fusions 
is unclear.
The work by Mizukami et al. provides rich information 
on breakpoints involving the RET oncogene. The information 
provided by Mizukami et al. should aid in the design of more 
sensitive molecular detection of these rearrangements in lung 
adenocarcinoma samples. The development of sensitive meth-
ods to detect rearrangements for DNA samples is particularly 
important for cases where RNA is not available or is of low 
quality. However, while many rearrangements are observed 
within relatively confined genomic regions, this study and 
other studies have shown that rearrangements do not occur 
at recurrent breakpoint positions nor retain specific sequence 
features characteristics of a single repair mechanism. This 
highlights the challenge for designing genomic PCR-based 
methods to cover all probable breakpoints, unless highly multi-
plexed. Therefore, this study implies that unbiased approaches 
using next-generation sequencing, including whole genome 
sequencing, sequencing after capture of selected regions of 
RNA or DNA encompassing the relevant breakpoints in RET, 
or transcriptome sequencing of RNA may be the best method-
ologies for the detection of RET chromosomal rearrangements 
in lung adenocarcinoma.
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